Healthcare ecosystem
As a global healthcare company, we recognize that meeting society’s expectations means going above and beyond what is legally required.
By fostering ethical dialogue with the healthcare ecosystem, we aim to advance diagnostic testing for infectious diseases. We strive to reduce noncompliance risks, generate learnings that can be applied to our organization and be recognized as a trusted partner in public health for all our stakeholders, with the sole interest of patients in mind.
We lead actions with the ambition of:
- Nurturing exchanges with patients, consumers and KOLs on major health challenges related to infectious diseases;
- Raising awareness of lay public and public decision makers on the medical and economic value of in vitro diagnostics;
- Ensuring ethical business conduct and regulatory compliance;
- Guaranteeing responsible data management.
bioMérieux has for many years developed, in a voluntary, dynamic and interactive manner, continuous dialogue with its internal and external stakeholders in order to make informed decisions that take their expectations into account. The shared vision is that dialogue with stakeholders is a privileged mode of cooperation for virtuously articulating the development of the Company and its long-term vision while generating value for the communities.
The medical value of in vitro diagnostics is demonstrated in the proof resource Evidence-based Diagnostics for Antimicrobial Stewardship (AMS)”.
This Selection of Publications contains summaries of major scientific articles, which provide independent evidence of the key role of diagnostics in supporting AMS Programs in both developed and developing settings, as well as showing the medical value of bioMérieux’s full range of AMS Solutions.
Download our brochure
- Filename
- EVIDENCE-BASED DX FOR AMS - Selection of Publications Update 2024 - FINAL - Interactive links - 03-24.pdf
- Size
- 3 MB
- Format
- application/pdf